Kadcycla Effective in Advanced Breast Cancer Patients Already Given Perjeta

Kadcycla Effective in Advanced Breast Cancer Patients Already Given Perjeta
Kadcyla (ado-trastuzumab emtansine, or T-DM1) may benefit HER2-positive metastatic breast cancer patients whose disease continues to progress despite prior treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab), according to the results of a retrospective study. The results, "T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab," published in the Journal of Clinical Oncology, demonstrate a meaningful tumor control rate in patients who received Perjeta prior to Kadcyla. Although Herceptin has markedly improved the treatment of HER2-positive breast cancer, most patients eventually require other treatments for their disease progression. Several HER2-directed therapies, including Tyverb (lapatinib), Perjeta, and Kadcyla, have been developed for these people. Kadcycla was approved by the U.S. Food and Drug Administration (FDA) as a second-line treatment for people with HER2-positive metastatic breast cancer, who had previously received standard therapy with Herceptin and a taxane, in 2013. However, Perjeta was later added to standard first-line treatment as part of neoadjuvant therapy, and the need arose to assess the activity of Kadcycla in patients previously exposed to Perjeta. Researchers used data from HER2-positive metastatic breast cancer patients at The Ohio State University Comprehensive Cancer Center, Yale Cancer Center, and The University of Texas MD Anderson Cancer Center to assess the outcomes of patients who r
Subscribe or to access all post and page content.